Decitabine in the treatment of myelodysplastic syndromes

References

• AbeleRClavelMDodionPThe EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2’-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomasEur J Cancer Clin Oncol198723192142449354
   PubMedGoogle Scholar
• AlessandrinoEPAmadoriSBarosiGEvidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of HematologyHaematologica200287128630612495903
   PubMed Web of Science ®Google Scholar
• American Cancer SocietyMultiple myeloma detailed guide2006 8/3/06
   Google Scholar
• American Cancer SocietyWhat are myelodysplastic syndromes and myelodysplastic/myeloproliferative diseases?2005 19/5/06 L:\\65589.pdf
   Google Scholar
• Aplastic Anemia & MDS International FoundationMyelodysplastic syndromes basic explanations2005 15/2/06
   Google Scholar
• AulCBowenDTYoshidaYPathogenesis, etiology and epidemiology of myelodysplastic syndromesHaematologica19988371869542325
   PubMed Web of Science ®Google Scholar
• BennettJMCatovskyDDanielMTProposals for the classification of the myelodysplastic syndromesBr J Haematol198251189996952920
   PubMed Web of Science ®Google Scholar
• BowenDCulliganDJowittSGuidelines for the diagnosis and therapy of adult myelodysplastic syndromesBr J Haematol200312018720012542475
   PubMed Web of Science ®Google Scholar
• CashenAShahAHelgetAA phase I pharmacokinetic trial of decitabine administered as a 3-hour infusion to patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS)Blood2005106527a8a
   Web of Science ®Google Scholar
• ChesonBDBennettJMKantarjianHReport of an international working group to standardize response criteria for myelodysplastic syndromesBlood2000963671411090046
   PubMed Web of Science ®Google Scholar
• ClavelMMonfardiniSFossaS5-Aza-2’-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer. Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary GroupAnn Oncol199233994001377488
   PubMed Web of Science ®Google Scholar
• CortesJGilesFO’BrienSResults of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disordersCancer2003972760612767088
   PubMed Web of Science ®Google Scholar
• CreusotFAcsGChristmanJKInhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-Aza-2’ deoxycytidineJ Biol Chem1982257204186173384
   PubMed Web of Science ®Google Scholar
• Dacogen [package insert]2006MGI Pharmaceuticals Inc
   Google Scholar
• DasPMSingalRDNA methylation and cancerJ Clin Oncol20042246324215542813
   PubMed Web of Science ®Google Scholar
• DaskalakisMNguyenTTNguyenCDemethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2’-deoxycytidine (decitabine) treatmentBlood200210029576412351408
   PubMed Web of Science ®Google Scholar
• FeldmanEJFarnesyltransferase inhibitors in myelodysplastic syndromeCurr Hematol Rep200541869015865870
   PubMedGoogle Scholar
• GanserAHoelzerDClinical course of myelodysplastic syndromesHematol Oncol Clin North Am19926607181613009
   PubMed Web of Science ®Google Scholar
• Garcia-ManeroGGoreSDFuture directions for the use of hypomethylating agentsSemin Hematol200542S50916015506
   PubMed Web of Science ®Google Scholar
• Garcia-ManeroGKantarjianHMSanchez-GonzalezBPhase I/II study of the combination of 5-aza-2’ -deoxycytidine with valproic acid in patients with leukemiaBlood20061083271916882711
   PubMed Web of Science ®Google Scholar
• GollobJASciambiCJPetersonBLPhase I trial of sequential low-dose 5-aza-2’-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinomaClin Cancer Res20061246192716899610
   PubMed Web of Science ®Google Scholar
• GreenbergPCoxCLeBeauMMInternational scoring system for evaluating prognosis in myelodysplastic syndromesBlood1997892079889058730
   PubMed Web of Science ®Google Scholar
• HofmannWKKoefflerHPMyelodysplastic syndromeAnnu Rev Med20055611615660498
   PubMed Web of Science ®Google Scholar
• IssaJPGarcia-ManeroGGilesFJPhase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2’-deoxycytidine (decitabine) in hematopoietic malignanciesBlood200410316354014604977
   PubMed Web of Science ®Google Scholar
• IssaJ-PJGharibyanVCortesJPhase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylateJ Clin Oncol20052339485615883410
   PubMed Web of Science ®Google Scholar
• JabbourEJGilesFJNew agents in myelodysplastic syndromesCurr Hematol Rep20054191915865871
   PubMedGoogle Scholar
• KaminskasEFarrellAAbrahamSApproval summary: azacitidine for treatment of myelodysplastic syndrome subtypesClin Cancer Res2005113604815897554
   PubMed Web of Science ®Google Scholar
• KantarjianHIssaJPRosenfeldCSDecitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyCancer2006106179480316532500
   PubMed Web of Science ®Google Scholar
• KantarjianHO’BrienSGilesFDecitabine low-dose schedule (100 mg/m2/course) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedulesBlood200510611 pt 1708a
   Web of Science ®Google Scholar
• KantarjianHOkiYGarcia-ManeroGResults of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemiaBlood200710952716882708
   PubMed Web of Science ®Google Scholar
• KantarjianHMO’BrienSCortesJResults of decitabine (5-aza-2’deoxycytidine) therapy in 130 patients with chronic myelogenous leukemiaCancer200398522812879469
   PubMed Web of Science ®Google Scholar
• KurzrockRMyelodysplastic syndrome overviewSemin Hematol200239182512214289
   PubMed Web of Science ®Google Scholar
• LeoneGTeofiliLVosoMTDNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemiasHaematologica20028713244112495905
   PubMed Web of Science ®Google Scholar
• ListAFVardimanJIssaJPMyelodysplastic syndromesHematology2004Washington DCAmerican Society of Hematology297317
   Google Scholar
• LubbertMRuterBSchmidMContinued low-dose decitabine (DAC) is an active first-line treatment of older AML patients: first results of a multicenter phase II studyBlood2005106527a
   Web of Science ®Google Scholar
• LubbertMWijermansPWRuterBHRe-treatment with low-dose 5-Aza-2’ deoxycytidine (decitabine) results in second remissions of previously responsive MDS patientsBlood2004104405a406a
   Web of Science ®Google Scholar
• McKeageKCroomKFDecitabine: in myelodysplastic syndromesDrugs200666951816740014
   PubMed Web of Science ®Google Scholar
• MomparlerRLBouffardDYMomparlerLFPilot phase I-II study on 5-aza-2’-deoxycytidine (Decitabine) in patients with metastatic lung cancerAnticancer Drugs19978358689180389
   PubMed Web of Science ®Google Scholar
• MomparlerRLRivardGEGygerMClinical trial on 5-aza-2’-deoxycytidine in patients with acute leukemiaPharmacol Ther198530277862433702
   PubMed Web of Science ®Google Scholar
• MundCHackansonBStresemannCCharacterization of DNA demethylation effects induced by 5-Aza-2’-deoxycytidine in patients with myelodysplastic syndromeCancer Res20056570869016103056
   PubMed Web of Science ®Google Scholar
• Myelodysplastic Syndromes FoundationFrequently asked questions about MDS [online]2006 URL: http://www.mds-foundation.org/patientinfo.htm
   Google Scholar
• Myelodysplastic Syndromes FoundationBennettJMThe myelodysplastic syndromes: a review for patients, families, friends, and healthcare professionals [online]2006 URL: http://www.mds-foundation.org/patientinfo.htm
   Google Scholar
• National Comprehensive Cancer NetworkClinical practice guidelines in oncology: myelodysplastic syndromes200642006
   Google Scholar
• O’BrienSIssaJPRavandiFDecitabine low-dose schedule (100 mg/m2/course) in myelodysplastic syndome (MDS). Comparison of 3 different dose schedulesJ Clin Oncol200523571s
   Web of Science ®Google Scholar
• PettiMCMandelliFZagonelVPilot study of 5-aza-2’-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients:preliminary resultsLeukemia19937Suppl 136417683355
   PubMed Web of Science ®Google Scholar
• PintoAZagonelVAttadiaV5-Aza-2’-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderlyBone Marrow Transplant19894Suppl 328322483349
   PubMed Web of Science ®Google Scholar
• PlumbJAStrathdeeGSluddenJReversal of drug resistance in human tumor xenografts by 2’-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoterCancer Res20006060394411085525
   PubMed Web of Science ®Google Scholar
• QuesnelBFenauxPP15INK4b gene methylation and myelodysplastic syndromesLeuk Lymphoma1999354374310609781
   PubMed Web of Science ®Google Scholar
• QuesnelBGuillermGVereecqueRMethylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progressionBlood1998912985909531610
   PubMed Web of Science ®Google Scholar
• RivardGEMomparlerRLDemersJPhase I study on 5-aza-2’-deoxycytidine in children with acute leukemiaLeuk Res19815453626173545
   PubMed Web of Science ®Google Scholar
• RuterBWijermansPWLubbertMSuperiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2’-deoxycytidine retreatment in high-risk myelodysplasia patientsCancer200610617445016532502
   PubMed Web of Science ®Google Scholar
• SabaHRosenfeldCIssaJPFirst report of the phase III North American trial of decitabine in advanced myelodysplastic syndrome (MDS)Blood200410423a
   Web of Science ®Google Scholar
• SabaHILubbertMWijermansPWResponse rates of phase 2 and phase 3 trials of decitabine (DAC) in patients with myelodysplastic syndromes (MDS)Blood2005106706a15802527
   PubMed Web of Science ®Google Scholar
• SabaHIWijermansPWDecitabine in myelodysplastic syndromesSemin Hematol200542S233116015501
   PubMed Web of Science ®Google Scholar
• SacchiSKantarjianHMO’BrienSChronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patientsCancer1999862641
   Web of Science ®Google Scholar
• SamlowskiWELeachmanSAWadeMEvaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylationJ Clin Oncol200523389790515753459
   PubMed Web of Science ®Google Scholar
• SantiniVKantarjianHMIssaJPChanges in DNA methylation in neoplasia: pathophysiology and therapeutic implicationsAnn Intern Med20011345738611281740
   PubMed Web of Science ®Google Scholar
• SchwartsmannGSchunemannHGoriniCNA phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancerInvest New Drugs200018839110830142
   PubMed Web of Science ®Google Scholar
• SekeresMAArsenic trioxide as a treatment for myelodysplastic syndromeCurr Hematol Rep20054596315610661
   PubMedGoogle Scholar
• SessaCten BokkelHWStoterGPhase II study of 5-aza-2’-deoxycytidine in advanced ovarian carcinoma. The EORTC Early Clinical Trials GroupEur J Cancer19902613781691012
   PubMed Web of Science ®Google Scholar
• SilvermanLRDemakosEPPetersonBLRandomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group BJ Clin Oncol20022024294012011120
   PubMed Web of Science ®Google Scholar
• StewartDJKurzrockROkiYPharmacodynamics of decitabine 5 days/week × 2 weeks in advanced cancersJ Clin Oncol200523suppl 16S219s
   Google Scholar
• ThibaultAFiggWDBerganRCA phase II study of 5-aza-2’-deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancerTumori1998848799619724
   PubMed Web of Science ®Google Scholar
• van GroeningenCJLeyvaAO’BrienAMPhase I and pharmacokinetic study of 5-aza-2’-deoxycytidine (NSC 127716) in cancer patientsCancer Res198646483162425959
   PubMed Web of Science ®Google Scholar
• VardimanJWHarrisNLBrunningRDThe World Health Organization (WHO) classification of the myeloid neoplasmsBlood2002100229230212239137
   PubMed Web of Science ®Google Scholar
• WijermansPLubbertMVerhoefGLow-dose 5-aza-2’-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patientsJ Clin Oncol2000189566210694544
   PubMed Web of Science ®Google Scholar
• WijermansPWKrulderJWHuijgensPCContinuous infusion of low-dose 5-Aza-2’-deoxycytidine in elderly patients with high-risk myelodysplastic syndromeLeukemia199711159001409
   PubMed Web of Science ®Google Scholar
• WilliamsonPJKrugerARReynoldsPJEstablishing the incidence of myelodysplastic syndromeBr J Haematol19948774357986716
   PubMed Web of Science ®Google Scholar